Rethinking Clinical Trials

MARCH 6, 2024

Pencina is a professor of biostatistics and bioinformatics and the vice dean for data science in the Duke University School of Medicine. The post March 6, 2024: In This Week’s PCT Grand Rounds, Public-Private Partnerships in Health AI appeared first on Rethinking Clinical Trials. Join the online meeting.

Bioinformatics 167

Bioinformatics Clinical Trials Clinical Trials Scientist 167

Pharmaceutical Technology

FEBRUARY 17, 2023

Oncology-focused bioinformatics firm M2GEN has entered a multi-year strategic collaboration with Zephyr AI to identify treatments and cures for cancer patients. M2GEN and Zephyr AI will together discover new cancer treatments and expanded use cases for better identifying new targets and enhancing clinical trial design.

Bioinformatics 147

Bioinformatics Production Clinical Trials Clinical Trials 147

Rethinking Clinical Trials

OCTOBER 17, 2023

Speaker Liz Turner, PhD Associate Professor, Biostatistics and Bioinformatics and Global Health Biostatistics and Study Design Core Co-Chair The post What Is the Intraclass Correlation Coefficient? appeared first on Rethinking Clinical Trials. Liz Turner discusses the intraclass correlation coefficient.

Bioinformatics 100

Bioinformatics Clinical Trials Clinical Trials Trials 100

Rethinking Clinical Trials

OCTOBER 17, 2023

Speaker Liz Turner, PhD Associate Professor, Biostatistics and Bioinformatics and Global Health Biostatistics and Study Design Core Co-Chair The post What Are the Types of CRT Designs? appeared first on Rethinking Clinical Trials. Liz Turner discusses the types of CRT designs.

Bioinformatics 100

Bioinformatics Clinical Trials Clinical Trials Trials 100

Rethinking Clinical Trials

OCTOBER 17, 2023

Speaker Liz Turner, PhD Associate Professor, Biostatistics and Bioinformatics and Global Health Biostatistics and Study Design Core Co-Chair The post How Does Clustering Affect Power and Detectable Difference? appeared first on Rethinking Clinical Trials. Liz Turner discusses how clustering affects power and detectable difference.

Bioinformatics 100

Bioinformatics Clinical Trials Clinical Trials Trials 100

Rethinking Clinical Trials

OCTOBER 17, 2023

Speaker Liz Turner, PhD Associate Professor, Biostatistics and Bioinformatics and Global Health Biostatistics and Study Design Core Co-Chair The post What Are the Reasons to Randomize Clusters Instead of Individuals? appeared first on Rethinking Clinical Trials.

Bioinformatics 100

Bioinformatics Clinical Trials Clinical Trials Trials 100

Rethinking Clinical Trials

OCTOBER 17, 2023

Speaker Liz Turner, PhD Associate Professor, Biostatistics and Bioinformatics and Global Health Biostatistics and Study Design Core Co-Chair The post How Do You Estimate the Degree of Clustering for Outcomes? appeared first on Rethinking Clinical Trials. Liz Turner discusses how to estimate the degree of clustering for outcomes.

Bioinformatics 100

Bioinformatics Clinical Trials Clinical Trials Trials 100

Rethinking Clinical Trials

OCTOBER 17, 2023

Speaker Liz Turner, PhD Associate Professor, Biostatistics and Bioinformatics and Global Health Biostatistics and Study Design Core Co-Chair The post What Are the Arguments For and Against the Stepped-Wedge Design? appeared first on Rethinking Clinical Trials.

Bioinformatics 100

Bioinformatics Clinical Trials Clinical Trials Trials 100

Rethinking Clinical Trials

OCTOBER 17, 2023

Speaker Liz Turner, PhD Associate Professor, Biostatistics and Bioinformatics and Global Health Biostatistics and Study Design Core Co-Chair The post What Is An Example of How to Choose a Study Design? appeared first on Rethinking Clinical Trials. Liz Turner discusses an example of how to choose a study design.

Bioinformatics 100

Bioinformatics Clinical Trials Clinical Trials Trials 100

Rethinking Clinical Trials

FEBRUARY 28, 2024

The global decentralized clinical trial market is expected to grow at a compound annual growth rate of 30.1% There is agreement that trials need to meet the people, at home and covering clinical trial deserts. Regardless of the trial inclusion and exclusion is routine. from 2021 to 2026.

Clinical Trials 111

Clinical Trials Clinical Trials Trials Clinical Research 111

BioTech 365

NOVEMBER 29, 2021

Global Biomarkers Markets, Technology & Competitive Landscape Report 2020-2021 & 2030: Focus on Proteomics, Metabolomics, Molecular Diagnostics, Drug Discovery, Clinical Trials, and Bioinformatics – ResearchAndMarkets.com Global Biomarkers Markets, Technology & Competitive Landscape Report 2020-2021 & 2030: Focus on Proteomics, (..)

Bioinformatics 40

Bioinformatics Clinical Trials Clinical Trials Marketing 40

pharmaphorum

MAY 27, 2022

This is the second in a two-part series examining how pharma can embrace the DEI agenda to create more effective medicines through more representative clinical trials. The same principles are increasingly being applied to clinical trials to improve diversity, mitigate bias, and reinforce inclusion in clinical trials.

Clinical Trials 80

Clinical Trials Clinical Trials Trials Packaging 80

pharmaphorum

OCTOBER 20, 2021

A software platform developed by Altoida that uses augmented reality and artificial intelligence to diagnose neurological diseases in their earliest stages is being tested in a five-year trial involving thousands of patients.

Trials 78

Trials Genome Genomics Bioinformatics 78

XTalks

NOVEMBER 7, 2022

Gleich, MD, FACS, Senior Vice President, Medical Department, and Dr. Christopher Huth, PhD, Senior Clinical Trial Manager, Clinical Trial Management. Liquid Biopsy Use in Oncology Clinical Trials. Optimal methods for bioinformatic analysis are still needed. percent show less reliability).

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

pharmaphorum

APRIL 8, 2021

million that will be used to take its personalised T cell therapy for lung and skin cancers through proof-of-concept trials. London-based Achilles has a bioinformatics platform called PELEUS that can identify clonal neoantigens in a patient, and an automated production platform – known as VELOS – to make the therapy.

Research 78

Research Bioinformatics Life Science Trials 78

pharmaphorum

APRIL 1, 2021

They go into bioinformatics”. There’s a lot of bioinformatics know-how and talent and a lot of good scientists who would like to better understand biology but don’t have the money to do it in wet settings. They go into bioinformatics.”. So what do they do? So, what do they do?

Bioinformatics 123

Bioinformatics Drugs Development Scientist 123

pharmaphorum

SEPTEMBER 16, 2022

It also bodes well for improving clinical trial success rates. The overarching desire to reduce in some way the “translational valley of death” of failed clinical trials is palpable. A notable issue with clinical trials is the homogeneity of the patient database. But mere volition does not enact results. About the interviewee.

Development 135

Development Research Drugs Clinical Trials 135

XTalks

APRIL 21, 2023

Biotech company Ultima Genomics has joined forces with Genome Insight, a bioinformatics-based biomedicine company, to overcome the caveat of cost and quality in WGS. Ultima Genomics will provide their high-throughput NGS instrument platform, the UG 100, and Genome Insight will provide the bioinformatics platform for data analysis.

Genome 97

Genome Genomics Bioinformatics Genetics 97

Scienmag

MAY 19, 2021

Proprietary bioinformatics, paired with comprehensive clinical curation results in reporting that defines clinically actionable, FDA-approved, and clinical trial drug options for the management of the patient’s cancer.

Genome 41

Genome Genomics Bioinformatics FDA Approval 41

pharmaphorum

SEPTEMBER 14, 2020

Genomics also means we will be able to stratify patients, based upon their genomic makeup, to make clinical trials much more efficient and targeted. While the clinical trial was successful in stopping seizures in around 72% of patients, which is an amazing result, nearly one third of patients did not respond.

Genome 119

Genome Genomics Medicine Gene 119

pharmaphorum

JANUARY 11, 2023

The prevailing trend – that looks set to continue into 2023 and beyond – is the direction of a smaller pot of money towards digital health ventures that can offer “clinical strength”; in other words, those that can demonstrate an evidence-based approach drawing on clinical trials, regulatory filings, and/or peer-reviewed publications.

Bioinformatics 75

Bioinformatics Clinical Trials Clinical Trials Production 75

XTalks

SEPTEMBER 28, 2020

Related: Liquid Biopsies Help Match Cancer Patients to Phase I Trials. The test is based on the detection of actionable genes – genes with known driver mutations that can be targeted by an approved therapy (or investigational therapies in clinical trials).

Gene 105

Gene DNA Life Science Genotype 105

XTalks

SEPTEMBER 5, 2023

Investigation of the possibility of VAED is crucial during clinical trials for decision-making on vaccine licensing by regulatory agencies. In the majority of cases, the risk of VAED is brought to light during preclinical stages or early clinical trial phases.

Vaccine 96

Vaccine Vaccination Development Clinical Trials 96

STAT News

MARCH 6, 2023

Unlike most people who receive medications yet to be cleared by the Food and Drug Administration, none of these patients is getting the vaccines as part of a clinical trial. Thirteen patients are waiting for their vaccine to be made. Typically, those patients pay nothing, in contrast to the foundation initiative.

Vaccine 98

Vaccine Vaccination Drugs Clinical Trials 98

XTalks

MAY 20, 2022

Here is a summary of the kind of work you can expect to do: Design and implement clinical trials for human diseases and treatment. There are different fields to explore as a clinical scientist — these include clinical bioinformatics, physiological sciences, pathology, medical physics and more. Liaise with stakeholders and scientists.

Scientist 105

Scientist Life Science Clinical Research Doctor 105

Scienmag

DECEMBER 10, 2020

Clinical trial at Moores Cancer Center at UC San Diego Health individualizes TIL therapy for patients with melanoma or head and neck cancers Credit: UC San Diego Health Sciences Since 2016, Bernard Thurman has undergone traditional treatments, experimental therapies and surgeries to counter the cancer within him, but nothing has successfully eradicated (..)

Clinical Trials 59

Clinical Trials Clinical Trials Trials Dermatology 59

pharmaphorum

MARCH 28, 2022

AION Labs’ third call for applications seeks computational biologists, bioinformatics and cheminformatics scientists, AI researchers, and antibody or protein engineers at academic and industry research labs worldwide to assemble a fully funded start-up company.

Pharma Companies 98

Pharma Companies Antibody Protein Development 98

XTalks

DECEMBER 13, 2023

The company’s sustained investment in R&D has led to a rapid expansion of its pipeline in 2023, with notable milestones such as four infectious disease vaccines in Phase III trials, including the recently submitted respiratory syncytial virus (RSV) vaccine for regulatory approval.

Genetics 111

Genetics Vaccination Vaccine DNA 111

Scienmag

JUNE 22, 2021

Credit: Insilco June 22, 2021, New York / Hong Kong — Insilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 million from biotechnology experts to progress Insilico Medicine’s current therapeutic programs into (..)

Medicine 55

Medicine Clinical Trials Clinical Trials Clinical Development 55

Scienmag

NOVEMBER 9, 2020

Credit: Insilico Tuesday, November 10, 2020 (9AM Beijing) – Insilico Medicine, a leader in deep generative reinforcement learning for target discovery, small molecule generation, and prediction of clinical trial outcomes, today announced that it entered into a multi-target drug discovery agreement with Janssen Pharmaceutica N.V.

Drugs 53

Drugs Clinical Trials Clinical Trials Medicine 53

Trialfacts

SEPTEMBER 12, 2024

Their work is driven by a profound understanding of disease biology and supported by advanced discovery platforms such as genetics and genomics, gene editing, bioinformatics, proteomics, bioengineering, image analysis, biobanks, disease-specific stem cell lines, and various animal models.

Research 52

Research Gene Editing Biobanking Bioinformatics 52

pharmaphorum

APRIL 15, 2021

“When the pandemic struck, we pivoted basically overnight to integrate many remote and digital processes – things like preparing submission dossiers remotely, but also decentralised clinical trials which are more patient-centric as the trial revolves around the patient and not the test center. In principle, this goes beyond medicines.

Development 76

Development Manufacturing Production Bioinformatics 76

The Pharma Data

JULY 27, 2021

Teneobio’s discovery platform, TeneoSeek, comprises genetically engineered animals (UniRat® and OmniFlic®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies. About Teneobio Teneobio, Inc.

Production 52

Production Antibody Sales Development 52

Scienmag

JUNE 22, 2021

CTCELLS Co., selected for ‘200 Baby Unicorns’ organized by MSS & KISED Credit: DGIST CTCELLS, established by Prof.

Development 55

Development Clinical Trials Clinical Trials Bioinformatics 55

The Pharma Data

DECEMBER 8, 2020

Under the Orphan Drug Act, FDA may provide grant funding toward clinical trial costs, tax advantages, FDA user-fee benefits, and seven years of market exclusivity in the United States following marketing approval by FDA.

Drugs 40

Drugs FDA Approval Marketing Containment 40

Scienmag

JUNE 17, 2021

AURORA, COLORADO, June 16, 2021 — Foresight Diagnostics, the emerging leader in blood-based lymphoma disease monitoring, announced today that clinical performance of its minimal residual disease (MRD) detection platform in diffuse large B-cell lymphoma (DLBCL) will be presented at the 16th International Conference on Malignant Lymphoma (ICML) (..)

Clinical Trials 40

Clinical Trials Clinical Trials Bioinformatics Allergies 40

The Pharma Data

JANUARY 10, 2021

I actually think neuroscience is going to heat up in 2021,” said Ben Zeskind , co-founder and CEO of Immuneering , which is using bioinformatics and computational biology to develop new drugs in this space, along with oncology and immuno-oncology. Moving on From the Amyloid Hypothesis. “I That is, faster approval of drugs in general.

Vaccination 52

Vaccination Vaccine Regulation Drugs 52